Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Hldgs is well-positioned for success with its innovative RaniPill capsule technology, which has the potential to revolutionize the delivery of biologic drugs. The company's pipeline of programs in obesity, osteoporosis, psoriasis, and psoriatic arthritis addresses target markets with significant unmet needs and potential for high margins. However, the company faces regulatory risk, as the FDA may refuse to approve an IDE for the RaniPill or require additional studies, and the political and regulatory landscape may change unfavorably.

Bears say

Rani Therapeutics Hldgs is a clinical-stage biotherapeutics company with a negative outlook due to potential clinical and commercial risks. While the RaniPill technology has the potential to provide a convenient alternative to painful injections, there is a risk that the safety and efficacy data may not replicate in larger studies. In addition, the company's reliance on generic or biosimilar APIs may limit market share and lead to competition from other long-acting injectable or oral delivery technologies. The recent capital raise has also increased the number of fully diluted shares, leading to a decrease in the 12-month price target.

RANI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 3 analysts, RANI has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.